Please check your internet connection and try again.
# Tabovoihep
## Overview
Tabovoihep is a brand name for a specific formulation of hepatitis B immune globulin (human). It is used for post-exposure prophylaxis against hepatitis B virus (HBV) infection.
## Primary Indications
* **Post-exposure prophylaxis of hepatitis B infection:** Following exposure to the hepatitis B virus, such as needlestick injuries, sexual exposure to an HBV-infected person, or perinatal exposure of an infant born to an HBV-infected mother.
## Adult Dosing
* **Post-exposure prophylaxis:** 0.06 mL/kg intramuscularly (IM) as a single dose. The dose can be repeated every 10 days if further exposure occurs.
* **For unvaccinated individuals exposed to HBV:** Administer within 7 days of exposure.
* **For unvaccinated individuals with sexual exposure:** Administer within 14 days of exposure.
* **For infants born to HBsAg-positive mothers:** Administer within 12 hours of birth.
## Pediatric Dosing
* **Infants born to HBsAg-positive mothers:** 0.5 mL IM as a single dose, administered within 12 hours of birth. This dose is independent of weight.
## Dose Adjustments
No specific dose adjustments are typically required for hepatic or renal impairment. However, caution is advised in patients with known hypersensitivity to immunoglobulins.
## Contraindications
* Known hypersensitivity to immune globulins or any component of the formulation.
* Individuals with a history of severe allergic reactions to human immunoglobulin preparations.
## Adverse Effects
* **Common:** Local reactions at the injection site (pain, redness, swelling). Headache, fever, chills, and malaise may occur.
* **Less Common:** Anaphylaxis (rare but serious), aseptic meningitis syndrome (rare), hemolytic anemia.
## Key Drug Interactions
* **Live virus vaccines:** Live virus vaccines (e.g., MMR, varicella) should be deferred for at least 3 months after administration of immune globulin. If an HBV vaccine is given concurrently with immune globulin, it should be administered in a different anatomical site.
* **Other Immunoglobulins:** Concurrent administration with other immunoglobulin products may interfere with the efficacy of either product.
## Monitoring
* Monitor for signs of hypersensitivity reactions, especially during and after administration.
* Hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) testing may be performed at appropriate intervals to confirm prevention of infection, though the exact timing depends on the exposure type and vaccination status.
## Clinical Pearls
* Tabovoihep is most effective when administered as soon as possible after exposure.
* For individuals requiring post-exposure prophylaxis, concurrent vaccination with the hepatitis B vaccine series is generally recommended, with the first dose given simultaneously with immune globulin but at a different site.
* Ensure adequate hydration to minimize the risk of renal-related adverse events, although this is more of a concern with higher doses or IVIG products.
**Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions.
